Logo
DesoBody Fat Dissolver 10ml Vial 5 x 10ml Box

DesoBody Fat Dissolver 10ml Vial 5 x 10ml Box

Deso

Aesthetic medicine injectable
  • Marketed in the UK and EU via professional aesthetic channels as a CE Marked fat Dissolving injectable device for localised body fat.
  • Manufactured under medical device quality management systems (e.g. ISO 13485) appropriate for aesthetic injectables.
  • Distributed only to licensed healthcare and aesthetic professionals in accordance with applicable national regulations and professional guidelines.
  • Intended use limited to subcutaneous injection for localised fat reduction by trained practitioners, following recognised intralipotherapy protocols.
Body fat-dissolving (lipolytic) injection

Description

DesoBody is an advanced fat-dissolving (lipolytic) injection formulated to target stubborn, localised pockets of body fat and refine body contours. Using deoxycholic acid (sodium deoxycholate) as its active ingredient, DesoBody damages adipocyte (fat cell) membranes, causing the stored fat to liquefy and be cleared gradually through the body’s lymphatic system. It is particularly suited to areas such as the arms, abdomen, flanks, hips, thighs, knees and other small, resistant fat deposits, offering a non-surgical alternative to liposuction when administered by qualified professionals. Compared with some older fat-dissolving products, DesoBody is reported to cause less swelling while offering effective reshaping of the treated area. Two Face Aesthetics supplies DesoBody either as a single 10 ml vial or as a box of five vials to accommodate different treatment plans and clinic workloads.

Bnefits

  • Targets localised pockets of body fat to refine and sculpt body contours.
  • Uses deoxycholic acid (sodium deoxycholate) to break down unwanted fat cells by disrupting their membranes.
  • Liquefied fat is removed naturally via the lymphatic system over time, avoiding surgery.
  • Provides a non-surgical, minimally invasive alternative to liposuction for suitable candidates.
  • Reported to cause less swelling and post-treatment discomfort than some older fat-dissolving formulations.
  • Suitable for multiple body areas including arms, abdomen, flanks, hips, thighs, knees and other stubborn fat sites.
  • Offered in flexible packaging options: single 10 ml vial or a pack of five 10 ml vials.
  • Can deliver long-lasting or effectively permanent reduction in treated fat cells when combined with a healthy lifestyle.
  • Designed for professional use in aesthetic clinics by trained medical practitioners familiar with intralipotherapy techniques.

Indications

  • Localised adiposity (stubborn fat pockets) on the body in adults.
  • Small to moderate fat deposits on arms, abdomen, flanks, hips, thighs, knees and similar areas that persist despite diet and exercise.
  • Patients seeking non-surgical body contouring and refinement rather than general weight loss.
  • Adjunctive body-contouring treatment in patients with stable or near-normal body weight who wish to improve silhouette and proportion.

Composition

      Formulation

      • Sterile, clear aqueous injectable solution for subcutaneous use.
      • Deoxycholic acid (sodium deoxycholate) at body-optimised concentration (commonly 1.25% in DesoBody) for controlled adipocyte lysis.
      • Formulated specifically for body treatment areas rather than delicate facial regions.
      • Non-animal origin raw materials; bio-resorbable and gradually cleared via natural metabolic pathways.
      • Intended exclusively for professional use by trained medical or aesthetic practitioners.

      Packaging

      • Single 10 ml vial of DesoBody fat-dissolving solution (for smaller treatment plans or top-up sessions).
      • Box of 5 x 10 ml vials (total 50 ml) for multi-session or multi-patient use in clinic settings, with each vial used for a single patient once opened.
      • Vials supplied in a branded outer carton with product identity, batch number and expiry date clearly marked.
      • Professional-use labelling indicating active ingredient (deoxycholic acid) and intended use on arms, abdomen, thighs and other areas with stubborn fat.

      Usage

      • For professional use only: DesoBody must be administered exclusively by licensed healthcare or aesthetic professionals trained in subcutaneous fat-dissolving techniques and local anatomy.
      • Pre-treatment:
      • • Take a full medical history and assess the patient’s suitability (localised fat vs. general obesity, skin quality, medical conditions).
      • • Identify and mark target areas with the patient standing to visualise natural contours.
      • • Obtain informed consent and document baseline measurements and photographs.
      • • Clean and disinfect the skin thoroughly; maintain strict aseptic technique throughout.
      • Dosage and injection technique (general guidance, not a substitute for official training):
      • • Inject strictly into the subcutaneous fat layer; avoid intradermal and intramuscular injection.
      • • Use appropriate needles or cannulas for body intralipotherapy, following the manufacturer’s and training-body protocols.
      • • Distribute the product in multiple small deposits or via fanning technique across the marked area to achieve uniform fat exposure.
      • • Typical target areas include arms, abdomen, hips, flanks, thighs, and knees; dosage per area depends on pinch thickness, size of the fat pocket and practitioner protocol.
      • • Do not exceed recommended total volume per session or treat excessively large body areas in a single treatment.
      • Session schedule:
      • • Treatments are commonly spaced 4–6 weeks apart to allow for adipocyte breakdown and lymphatic clearance.
      • • Most cases require a series of 2–4 sessions, with the exact number tailored to patient goals, area size and individual response.
      • Aftercare:
      • • Advise patients that swelling, redness, tenderness, bruising and a feeling of firmness or lumpiness are expected in the treated area for several days.
      • • Recommend avoiding strenuous exercise, saunas, hot baths, sunbeds and alcohol for a few days post-treatment.
      • • Encourage adequate hydration and a healthy lifestyle to support lymphatic clearance.
      • • Instruct patients not to massage the treated area unless specifically advised by the practitioner.
      • • Provide guidance on appropriate pain relief (e.g. paracetamol if suitable) and when to seek medical review.
      • Important:
      • • Always follow up-to-date protocols provided by training courses and official product literature.
      • • Do not use in patients with contraindications; stop treatment and evaluate if unexpected reactions occur.
      • • DesoBody is not a weight-loss treatment and should only be used for localised fat reduction.

      Contraindications

      • Known hypersensitivity or allergy to deoxycholic acid (sodium deoxycholate) or any excipient in the formulation.
      • Pregnancy or breastfeeding.
      • Patients under 18 years of age.
      • Obesity or generalised adiposity where localised injection therapy is inappropriate as a weight-loss method.
      • Active skin or soft-tissue infection, inflammation, dermatitis or open wounds at the intended injection site.
      • Significant hepatic, renal, uncontrolled endocrine or metabolic disease unless specifically assessed and approved by a physician.
      • Severe autoimmune disease, immunosuppression or other conditions that significantly impair wound healing.
      • Uncontrolled bleeding disorders or concurrent anticoagulant/antiplatelet therapy that substantially increases the risk of bleeding or bruising, unless carefully managed.
      • History of severe anaphylactic reactions or multiple severe allergies to injectable products.
      • Presence of permanent fillers, implants or other foreign bodies in the target area unless safety and compatibility are clearly established.
      • Very thin subcutaneous fat layer where safe injection depth cannot be reliably maintained.

      Adverse Effects

      • Very common and expected: pain, burning or stinging at injection sites; erythema (redness); swelling; warmth; tenderness; and induration in the treated area, typically resolving over days to a couple of weeks.
      • Common: bruising or haematoma formation; temporary nodules or lumpiness as part of the inflammatory and lipolytic response.
      • Occasional: transient altered sensation such as numbness, tingling or hypersensitivity in the treated region.
      • Less common: local infection (e.g. cellulitis or abscess) if aseptic technique is not strictly followed, requiring appropriate medical management.
      • Possible: transient hyperpigmentation or textural changes in predisposed individuals, particularly if significant inflammation or sun exposure occurs during healing.
      • Rare but more serious: excessive or prolonged inflammation, persistent nodules, or uneven contouring that may require further medical evaluation or corrective treatment.
      • Very rare but severe: tissue necrosis, ulceration, nerve damage or vascular compromise following incorrect injection technique (e.g. intradermal or intravascular injection); these require urgent specialist intervention.
      • Allergic or hypersensitivity reactions (local or systemic) to any component of the product, which may present as persistent swelling, rash, pruritus, difficulty breathing or other systemic symptoms; immediate medical attention is required.

      Storage Conditions

      • Store in a cool, dry place at controlled room temperature within the range specified by the manufacturer (typically between 2°C and 25°C).
      • Do not freeze; protect vials from extreme heat and direct sunlight.
      • Keep vials in their original outer carton until use to protect from light and contamination.
      • Do not use after the expiry date printed on the packaging.
      • Do not use vials that are cracked, leaking or if the solution is discoloured or contains visible particles.
      • Keep out of the sight and reach of children.
      • Dispose of used vials, needles and syringes as clinical sharps waste in accordance with local regulations.

      Duration

      Treatment is usually performed as a short course of 2\u20134 sessions spaced approximately 4\u20136 weeks apart. Each session takes place in-clinic and the lipolytic process continues for several weeks after injection. Fat cells destroyed in the treated area are considered permanently removed; overall duration of visible contouring results depends on the patient maintaining a stable weight and healthy lifestyle. Maintenance or additional sessions may be considered if residual or new fat deposits appear over time.

      Onset

      The breakdown of fat cells begins soon after injection, but visible changes develop progressively. Patients typically experience peak swelling and tenderness in the first few days, followed by gradual reduction in swelling over 1\u20132 weeks. Initial contour improvements usually become noticeable within 3\u20134 weeks after treatment, with full results commonly observed 6\u20138 weeks after the final session. Individual results and timelines vary depending on metabolism, lifestyle and treatment area.

      Browse more Aesthetic medicine injectable

      Top Treatments

      Top Cities in the UK